Meu SciELO
Serviços customizadosServiços Personalizados
Journal
Artigo
Inglês (pdf)
Artigo em XML
Referências do artigo
Tradução automática
Enviar este artigo por emailIndicadores
Citado por SciELO 
Acessos
Links relacionados
Citado por Google 
Similares em
SciELO 
Similares em Google
Compartilhar
Permalink
Revista de la OFIL
versão On-line ISSN 1699-714Xversão impressa ISSN 1131-9429
Resumo
BRICENO-CASADO, MP; RIOS-SANCHEZ, E e GIL-SIERRA, MD. Real long-term data of dupilumab in atopic dermatitis. Rev. OFIL·ILAPHAR [online]. 2020, vol.30, n.1, pp.25-27. Epub 18-Jan-2021. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x2020000100008.
Objectives:
Dupilumab is the first biological drug indicated in atopic dermatitis (AD). The aim of this study is to assess effectiveness and safety of dupilumab in moderate-severe AD in clinical practice, and the quality of life of treated patients.
Methods:
Descriptive retrospective study was conducted. Effectiveness was measured by SCORingAtopic Dermatitis (SCORAD). Primary endpoint was SCORAD-75; secondary endpoints were SCORAD-90 and “total clearance”, at week 4, 12, 24 and 48. Safety was evaluated according to adverse events profile. Quality of life was assessed by Dermatology Life Quality Index (DLQI) at week 0 and 48.
Results:
At week 4, 2 patients presented SCORAD-75, none presented SCORAD-90 or clearance. At week 12, 2 patients showed SCORAD-75, 2 SCORAD-90 and one clearance. At weeks 24 and 48, 3 patients presented SCORAD-90 and 3 clearance. All patients presented mild-moderate adverse events. DLQI at week 48 was 0.7.
Conclusions:
Dupilumab presented adequate effectiveness and safety, improving quality of life of treated patients.
Palavras-chave : Atopic dermatitis; dupilumab; effectiveness; safety; quality of life.
